1. Articles in category: Human Interest

    1-24 of 161 1 2 3 4 5 6 7 »
    1. Therapeutic Innovations for Targeting Childhood Neuroblastoma: Implications of the Neurokinin-1 Receptor System.

      Therapeutic Innovations for Targeting Childhood Neuroblastoma: Implications of the Neurokinin-1 Receptor System.

      Anticancer Res. 2017 11;37(11):5911-5918

      Authors: Berger M, VON Schweinitz D

      Abstract Neuroblastoma is the most common solid extracranial malignant tumor in children. Despite recent advances in the treatment of this heterogenous tumor with surgery and chemotherapy, the prognosis in advanced stages remains poor.

      Read Full Article
    2. Immune Thrombocytopenia in a Child with Neuroblastoma.

      Immune Thrombocytopenia in a Child with Neuroblastoma.

      Case Rep Pediatr. 2017;2017:1329489

      Authors: Ikizoglu HT, Ayan I, Tokat F, Tecimer T, Topuzlu Tekant G

      Abstract Thrombocytopenia is a frequent finding in patients with solid tumors. It is usually caused by bone marrow infiltration or by myelosuppression due to anticancer therapy; however immune thrombocytopenia (ITP) associated with solid tumors is rare. Neuroblastoma is the most common extracranial solid tumor in children.

      Read Full Article
      Mentions: Bone Marrow
    3. WNT signaling, the development of the sympathoadrenal-paraganglionic system and neuroblastoma.

      WNT signaling, the development of the sympathoadrenal-paraganglionic system and neuroblastoma.

      Cell Mol Life Sci. 2017 Oct 22;:

      Authors: Becker J, Wilting J

      Abstract Neuroblastoma (NB) is a tumor of the sympathoadrenal system arising in children under 15 years of age. In Germany, NB accounts for 7% of childhood cancer cases, but 11% of cancer deaths.

      Read Full Article
    4. Treatment and survival of childhood neuroblastoma: Evidence from a population-based study in the United States.

      Treatment and survival of childhood neuroblastoma: Evidence from a population-based study in the United States.

      Pediatr Hematol Oncol. 2017 Oct 17;:1-11

      Authors: Coughlan D, Gianferante M, Lynch CF, Stevens JL, Harlan LC

      Abstract BACKGROUND: Childhood neuroblastoma describes a heterogeneous group of extracranial solid tumors, that are treated per risk profile. We sought to describe treatment patterns and survival using population-based data from throughout the United States.

      Read Full Article
      Mentions: Treatment COG MYCN
    5. New study finds childhood cancer survivors commonly stay at jobs to keep health insurance

      New study finds childhood cancer survivors commonly stay at jobs to keep health insurance

      ( University of Utah Health ) The results of a national cancer survey find a significant number of childhood cancer survivors are worried about keeping their health insurance, to the point of letting it affect their career decisions. The findings were published today in JAMA Oncology.

      Read Full Article
    6. NIH Funds Pediatric Data Resource Center.

      NIH Funds Pediatric Data Resource Center.

      Cancer Discov. 2017 Oct 11;:

      Authors:

      Abstract Children's Hospital of Philadelphia will lead a collaborative effort-funded with $14.8 million from the NIH-to pool genomic and phenotypic data from tens of thousands of patients to study the causes of pediatric cancer and structural birth defects.

      PMID: 29021134 [PubMed - as supplied by publisher]

      Read Full Article
    7. Genetic Variations of GWAS-Identified Genes and Neuroblastoma Susceptibility: a Replication Study in Southern Chinese Children.

      Genetic Variations of GWAS-Identified Genes and Neuroblastoma Susceptibility: a Replication Study in Southern Chinese Children.

      Transl Oncol. 2017 Oct 09;10(6):936-941

      Authors: He J, Zou Y, Wang T, Zhang R, Yang T, Zhu J, Wang F, Xia H

      Abstract Neuroblastoma is one of the most commonly diagnosed solid cancers for children, and genetic factors may play a critical role in neuroblastoma development.

      Read Full Article
    8. Frequency and proliferative response of circulating invariant natural killer T cells in pediatric patients with malignant solid tumors.

      Frequency and proliferative response of circulating invariant natural killer T cells in pediatric patients with malignant solid tumors.

      Pediatr Surg Int. 2017 Oct 10;:

      Authors: Hishiki T, Mise N, Harada K, Ihara F, Takami M, Saito T, Terui K, Nakata M, Komatsu S, Yoshida H, Motohashi S

      Read Full Article
    9. Legumain correlates with neuroblastoma differentiation and can be used in prodrug design.

      Legumain correlates with neuroblastoma differentiation and can be used in prodrug design.

      Chem Biol Drug Des. 2017 Oct 10;:

      Authors: Zhang M, Jiang Z, Chen S, Wu Z, Chen K, Wu Y

      Abstract Neuroblastoma (NB) is a highly malignant solid tumor in children. The cysteine endopeptidase legumain is expressed in adult solid tumors, but its expression in NB has not been examined.

      Read Full Article
    10. Diet, exercise modifications can have ‘tremendous impact’ on pediatric cancer outcomes

      Joya Chandra Keri Schadler Diet and exercise may improve treatment outcomes among pediatric patients with cancer, according to a study conducted at The University of Texas MD Anderson Children’s Cancer Hospital. In addition, introducing energy balance interventions may reduce the risk for late effects during survivorship. Researchers at MD Anderson reviewed 67 pediatric oncology studies to evaluate the relationship between diet and exercise.

      Read Full Article
      Mentions: Treatment
    11. GD2 Specific CAR and Interleukin-15 Expressing Autologous NK T-cells to Treat Children With Neuroblastoma

      GD2 Specific CAR and Interleukin-15 Expressing Autologous NK T-cells to Treat Children With Neuroblastoma

      Condition :   Neuroblastoma Interventions :   Genetic: GINAKIT Cells;   Drug: Cyclophosphamide;   Drug: Fludarabine Sponsors :   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   Texas Children's Hospital Not yet recruiting

      Read Full Article
      Mentions: T-Cells
    12. Researchers Identify Gene Variants Linked to a High-Risk Children's Cancer

      Pediatric researchers investigating the childhood cancer neuroblastoma have identified common gene variants that raise the risk of an aggressive form of that disease. The discovery, in the MMP20 gene, may assist doctors in better diagnosing subtypes of neuroblastoma.

      Read Full Article
      Mentions: Genetics
    13. Researchers identify gene variants linked to a high-risk children's cancer

      Researchers identify gene variants linked to a high-risk children's cancer

      ( Children's Hospital of Philadelphia ) Pediatric researchers investigating the childhood cancer neuroblastoma have identified common gene variants that raise the risk of an aggressive form of that disease. The discovery may assist doctors in better diagnosing subtypes of neuroblastoma.

      Read Full Article
      Mentions: Genetics
    14. When good immune cells turn bad

      When good immune cells turn bad

      Investigators at the Children's Center for Cancer and Blood Diseases at Children's Hospital Los Angeles have identified new findings about an immune cell - called a tumor-associated macrophage - that promotes cancer instead of fighting it. They have identified the molecular pathway, known as STAT3, as the mechanism the immune cell uses to foster neuroblastoma, a pediatric cancer, and have demonstrated use of a clinically available agent, ruxolitinib, to block the pathway.

      Read Full Article
    15. Common variants in MMP20 at 11q22.2 predispose to 11q deletion and neuroblastoma risk.

      Common variants in MMP20 at 11q22.2 predispose to 11q deletion and neuroblastoma risk.

      Nat Commun. 2017 Sep 18;8(1):569

      Authors: Chang X, Zhao Y, Hou C, Glessner J, McDaniel L, Diamond MA, Thomas K, Li J, Wei Z, Liu Y, Guo Y, Mentch FD, Qiu H, Kim C, Evans P, Vaksman Z, Diskin SJ, Attiyeh EF, Sleiman P, Maris JM, Hakonarson H

      Read Full Article
      Mentions: MYCN
    16. Cell surface protein may offer big target in treating high-risk childhood cancers

      Cell surface protein may offer big target in treating high-risk childhood cancers

      Oncology researchers studying high-risk children's cancers have identified a protein that offers a likely target for immunotherapy--harnessing the immune system in medical treatments.

      In cell cultures and animal models, a potent drug attached to an...

      Read Full Article
      Mentions: Immunotherapy
    17. Does Health Insurance Status Affect Childhood Cancer Survival?

      Does Health Insurance Status Affect Childhood Cancer Survival?

      Privately insured children and those with Medicaid at the time of a cancer diagnosis experience largely similar survival trends, with slight evidence for an increased risk of cancer death in children who were uninsured at diagnosis, finds a new study from the Brown School at Washington University in St. Louis.

      Read Full Article
    18. Cell surface protein may offer big target in treating high-risk childhood cancers

      Cell surface protein may offer big target in treating high-risk childhood cancers

      ( Children's Hospital of Philadelphia ) Oncology researchers studying high-risk children's cancers have identified a protein that offers a likely target for immunotherapy -- harnessing the immune system in medical treatments. In cell cultures and animal models, a potent drug attached to an antibody selectively zeroes in on cancer cells without harming healthy cells.

      Read Full Article
    19. Prolonged Isotretinoin in Ultra High-Risk Neuroblastoma.

      Prolonged Isotretinoin in Ultra High-Risk Neuroblastoma.

      J Pediatr Hematol Oncol. 2017 Jan;39(1):e33-e35

      Authors: Cash T, Alazraki A, Qayed M, Katzenstein HM

      Abstract Patients with high-risk neuroblastoma remain a therapeutic challenge with significant numbers of patients failing to respond sufficiently to initial therapy. These patients with poor response to induction are considered as ultra high-risk and are in need of novel treatment strategies.

      Read Full Article
      Mentions: Treatment
    20. Study shows incisionless surgery with MR-HIFU effective in destroying painful bone tumors

      Study shows incisionless surgery with MR-HIFU effective in destroying painful bone tumors

      Doctors from the Sheikh Zayed Institute for Pediatric Surgical Innovation at Children's National Health System have completed a clinical trial that demonstrates how osteoid osteoma, a benign but painful bone tumor that commonly occurs in children and young adults, can be safely and successfully treated using an incisionless surgery method called magnetic resonance-guided high-intensity focused ultrasound (MR-HIFU).

      Read Full Article
      Mentions: Surgery
    1-24 of 161 1 2 3 4 5 6 7 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles